Left: mouse astrocytes (green) before reprogramming; Right: neurons (red) induced from mouse astrocytes after reprogramming with PTB antisense oligonucleotide treatment.
UC San Diego Health Sciences
Inhibiting a single gene converts many cell types directly into dopamine-producing neurons
Xiang-Dong Fu, PhD, has never been more excited about something in his entire career. He has long studied the basic biology of RNA, a genetic cousin of DNA, and the proteins that bind it. But a single discovery has launched Fu into a completely new field: neuroscience.
For decades, Fu and his team at University of California San Diego School of Medicine studied a protein called PTB, which is well known for binding RNA and influencing which genes are turned “on” or “off” in a cell. To study the role of a protein like PTB, scientists often manipulate cells to reduce the amount of that protein, and then watch to see what happens.
Several years ago, a postdoctoral researcher working in Fu’s lab was taking that approach, using a technique called siRNA to silence the PTB gene in connective tissue cells known as fibroblasts. But it’s a tedious process that needs to be performed over and over. He got tired of it and convinced Fu they should use a different technique to create a stable cell line that’s permanently lacking PTB. At first, the postdoc complained about that too, because it made the cells grow so slowly.
But then he noticed something odd after a couple of weeks — there were very few fibroblasts left. Almost the whole dish was instead filled with neurons.
In this serendipitous way, the team discovered that inhibiting or deleting just a single gene, the gene that encodes PTB, transforms several types of mouse cells directly into neurons.
More recently, Fu and Hao Qian, PhD, another postdoctoral researcher in his lab, took the finding a big step forward, applying it in what could one day be a new therapeutic approach for Parkinson’s disease and other neurodegenerative diseases. Just a single treatment to inhibit PTB in mice converted native astrocytes, star-shaped support cells of the brain, into neurons that produce the neurotransmitter dopamine. As a result, the mice’s Parkinson’s disease symptoms disappeared.
The study is published June 24, 2020 in Nature.
“Researchers around the world have tried many ways to generate neurons in the lab, using stem cells and other means, so we can study them better, as well as to use them to replace lost neurons in neurodegenerative diseases,” said Fu, who is a Distinguished Professor in the Department of Cellular and Molecular Medicine at UC San Diego School of Medicine. “The fact that we could produce so many neurons in such a relatively easy way came as a big surprise.”
There are several different ways to mimic Parkinson’s disease in mice. In this case, the researchers applied a dopamine look-a-like molecule to poison neurons that produce dopamine. As a result, the mice lose dopamine-producing neurons and develop symptoms similar to Parkinson’s disease, such as movement deficiencies.
The treatment works like this: The researchers developed a noninfectious virus that carries an antisense oligonucleotide sequence — an artificial piece of DNA designed to specifically bind the RNA coding for PTB, thus degrading it, preventing it from being translated into a functional protein and stimulating neuron development.
Antisense oligonucleotides, also known as designer DNA drugs, are a proven approach for neurodegenerative and neuromuscular diseases — study co-author, Don Cleveland, PhD, pioneered the technology, and it now forms the basis for a Food and Drug Administration (FDA)-approved therapy for spinal muscular atrophy and several other therapies currently in clinical trials. Cleveland is chair of the Department of Cellular and Molecular Medicine at UC San Diego School of Medicine and member of the Ludwig Institute for Cancer Research, San Diego.
The researchers administered the PTB antisense oligonucleotide treatment directly to the mouse’s midbrain, which is responsible for regulating motor control and reward behaviors, and the part of the brain that typically loses dopamine-producing neurons in Parkinson’s disease. A control group of mice received mock treatment with an empty virus or an irrelevant antisense sequence.
In the treated mice, a small subset of astrocytes converted to neurons, increasing the number of neurons by approximately 30 percent. Dopamine levels were restored to a level comparable to that in normal mice. What’s more, the neurons grew and sent their processes into other parts of brain. There was no change in the control mice.
By two different measures of limb movement and response, the treated mice returned to normal within three months after a single treatment, and remained completely free from symptoms of Parkinson’s disease for the rest of their lives. In contrast, the control mice showed no improvement.
“I was stunned at what I saw,” said study co-author William Mobley, MD, PhD, Distinguished Professor of Neurosciences at UC San Diego School of Medicine. “This whole new strategy for treating neurodegeneration gives hope that it may be possible to help even those with advanced disease.”
What is it about PTB that makes this work? “This protein is present in a lot of cells,” Fu said. “But as neurons begin to develop from their precursors, it naturally disappears. What we’ve found is that forcing PTB to go away is the only signal a cell needs to turn on the genes needed to produce a neuron.”
Of course, mice aren’t people, he cautioned. The model the team used doesn’t perfectly recapitulate all essential features of Parkinson’s disease. But the study provides a proof of concept, Fu said.
Next, the team plans to optimize their methods and test the approach in mouse models that mimic Parkinson’s disease through genetic changes. They have also patented the PTB antisense oligonucleotide treatment in order to move forward toward testing in humans.
“It’s my dream to see this through to clinical trials, to test this approach as a treatment for Parkinson’s disease, but also many other diseases where neurons are lost, such as Alzheimer’s and Huntington’s diseases and stroke,” Fu said. “And dreaming even bigger — what if we could target PTB to correct defects in other parts of the brain, to treat things like inherited brain defects?
“I intend to spend the rest of my career answering these questions.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Applicability of optical coherence tomography angiography (OCTA) imaging in Parkinson’s diseaseon March 9, 2021 at 2:24 am
To evaluate the significance of motion artifacts in optical coherence tomography angiography (OCTA) images of patients with Parkinson’s disease (PD) and healthy controls. In this prospective, ...
- Sheffield scientists awarded £1.2 million to design Parkinson’s drugon March 9, 2021 at 2:09 am
Scientists from the University of Sheffield have been awarded £1.2 million to develop a drug to protect dopamine-producing brain cells and slow down the progression of Parkinson’s Disease.
- Study: Type 2 diabetes can increase risk of Parkinson's diseaseon March 8, 2021 at 9:24 pm
Research from Queen Mary University of London has concluded that there is convincing evidence that type 2 diabetes is associated with an increased risk of Parkinson's disease.
- UK charity announces £1.2 million funding to design Parkinson's drugon March 8, 2021 at 4:20 pm
Parkinson's UK, the largest charitable funder of Parkinson's research in Europe, is investing up to £1.2 million into a pioneering one-year project in partnership with the University of Sheffield. The ...
- A Swing and a Hit? Golf May Help With Parkinson'son March 8, 2021 at 1:55 pm
Playing golf improves mobility and balance in Parkinson's better than tai chi, the gold standard exercise for improved balance and falls prevention in this patient population, early research suggests.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Designer DNA drugs
- Research pinpoints unique drug target in antibiotic resistant bacteriaon March 8, 2021 at 1:38 pm
Researchers have identified a critical mechanism that allows deadly bacteria to gain resistance to antibiotics.
- Time needed to sequence key molecules could be reduced from years to minuteson March 8, 2021 at 12:01 pm
Using a nanopore, researchers have demonstrated the potential to reduce the time required for sequencing a glycosaminoglycan—a class of long chain-linked sugar molecules as important to our biology as ...
- Global Hydrogels Market Analysis & Forecasts 2020-2025 - Growing Use in Wound Care Products and Drug Delivery Systems (DDS)on March 8, 2021 at 3:46 am
The "Hydrogels - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. The global market for Hydrogel is projected to reach US$15.3 billion by 2025, driven ...
- 4 SPACs for the Futureon March 6, 2021 at 8:18 am
D capture software company, and two biotechs are about to hit the public markets. Smart investors can get in now via special purpose acquisition companies.
- The designer turning high fashion into super prime property with sex, drugs and rock 'n' roll flareon March 2, 2021 at 4:00 pm
There’s only one architect, with the tattoos of a rock star and the soul of a philosopher, who brings the house ...